written on 20.05.2014

GlaxoSmithKline's Arzerra flunks lymphoma trial, dashing plans for expanded use


GlaxoSmithKline has missed out on a big new market for its blood cancer drug Arzerra. Approved to treat chronic lymphocytic leukemia, Arzerra (ofatumumab) failed to pass the test in a B-cell lymphoma trial. And now, Glaxo officials say they're giving up on the indication.